COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01619085




Registration number
NCT01619085
Ethics application status
Date submitted
6/06/2012
Date registered
14/06/2012
Date last updated
11/08/2020

Titles & IDs
Public title
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Scientific title
An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Secondary ID [1] 0 0
2011-002766-21
Secondary ID [2] 0 0
1199.33
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BIBF 1120

Experimental: BIBF 1120 - patient to receive a capsule containing BIBF 1120 twice a day


Treatment: Drugs: BIBF 1120
BIBF 1120 Bis in die (twice a day)

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of Adverse Events (AE) - This is the measure for percentage of patients with adverse events observed during the trial. The incidence of AEs (% of patients) over the course of the trial, including the incidence of serious AEs, AEs leading to discontinuation, and fatal AEs are presented.
Timepoint [1] 0 0
From first drug administration until treatment period, in total up to 56.3 months.

Eligibility
Key inclusion criteria
Inclusion criteria:

1. Signed Informed Consent consistent with International Conference on Harmonisation-Good
Clinical Practices (ICH-GCP) and local laws prior to trial participation.

2. Patients from trials 1199.32 or 1199.34 who completed the 52 weeks treatment period
and performed the follow-up visit.
Minimum age
40 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) > 1.5 fold Upper
Limit of Normal (ULN) (Patients who completed the parent trial with transaminase
values > 1.5 fold ULN but < 3 fold ULN are considered eligible)

2. Bilirubin > 1.5 fold ULN

3. Bleeding risk

4. Planned major surgery within the next 3 months, including lung transplantation, major
abdominal or major intestinal surgery.

5. New major thrombo-embolic events developed after completion of the parent trial.

6. Time period > 12 weeks between Visit 9 of the parent trial and Visit 2 of this study.

7. Usage of any investigational drug after completion of the parent trial or planned
usage of a specific investigational drug during the course of this trial.

8. A disease or condition which in the opinion of investigator may put the patient at
risk because of participation in this trial or limit the patients' ability to
participate in this trial.

9. Alcohol or drug abuse which in the opinion of the investigator would interfere with
trial participation.

10. Pregnant women or women who are breast feeding or of child bearing potential not using
two effective methods of birth control (one barrier and one highly effective
non-barrier) for at least 1 month prior to Visit 2 and/or not committing to using it
until 3 months after end of treatment.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Repatriation General Hospital - Concord
Recruitment hospital [3] 0 0
Frankston Hospital - Frankston
Recruitment hospital [4] 0 0
Alfred Hospital PO Box - Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2137 - Concord
Recruitment postcode(s) [3] 0 0
3199 - Frankston
Recruitment postcode(s) [4] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New Hampshire
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Oregon
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
Rhode Island
Country [18] 0 0
United States of America
State/province [18] 0 0
South Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Vermont
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Belgium
State/province [24] 0 0
Brussel
Country [25] 0 0
Belgium
State/province [25] 0 0
Bruxelles
Country [26] 0 0
Belgium
State/province [26] 0 0
Leuven
Country [27] 0 0
Belgium
State/province [27] 0 0
Yvoir
Country [28] 0 0
Canada
State/province [28] 0 0
Nova Scotia
Country [29] 0 0
Canada
State/province [29] 0 0
Ontario
Country [30] 0 0
Chile
State/province [30] 0 0
Santiago de Chile
Country [31] 0 0
China
State/province [31] 0 0
Beijing
Country [32] 0 0
China
State/province [32] 0 0
Changsha
Country [33] 0 0
China
State/province [33] 0 0
Chengdu
Country [34] 0 0
China
State/province [34] 0 0
Nanchang
Country [35] 0 0
China
State/province [35] 0 0
Shanghai
Country [36] 0 0
China
State/province [36] 0 0
Shenyang
Country [37] 0 0
China
State/province [37] 0 0
Xi'An
Country [38] 0 0
China
State/province [38] 0 0
Yinchuan
Country [39] 0 0
Czechia
State/province [39] 0 0
Prague 4
Country [40] 0 0
Czechia
State/province [40] 0 0
Prague 8
Country [41] 0 0
Czechia
State/province [41] 0 0
Usti nad Labem
Country [42] 0 0
Finland
State/province [42] 0 0
Helsinki
Country [43] 0 0
Finland
State/province [43] 0 0
Vantaa
Country [44] 0 0
France
State/province [44] 0 0
Bobigny
Country [45] 0 0
France
State/province [45] 0 0
Dijon
Country [46] 0 0
France
State/province [46] 0 0
Lille Cedex
Country [47] 0 0
France
State/province [47] 0 0
Lyon cedex
Country [48] 0 0
France
State/province [48] 0 0
Marseille
Country [49] 0 0
France
State/province [49] 0 0
Montpellier
Country [50] 0 0
France
State/province [50] 0 0
Nice
Country [51] 0 0
France
State/province [51] 0 0
Paris
Country [52] 0 0
France
State/province [52] 0 0
Reims
Country [53] 0 0
France
State/province [53] 0 0
Rennes Cedex 9
Country [54] 0 0
France
State/province [54] 0 0
Toulouse
Country [55] 0 0
Germany
State/province [55] 0 0
Bamberg
Country [56] 0 0
Germany
State/province [56] 0 0
Berlin-Buch
Country [57] 0 0
Germany
State/province [57] 0 0
Berlin
Country [58] 0 0
Germany
State/province [58] 0 0
Coswig
Country [59] 0 0
Germany
State/province [59] 0 0
Donaustauf
Country [60] 0 0
Germany
State/province [60] 0 0
Essen
Country [61] 0 0
Germany
State/province [61] 0 0
Freiburg/Breisgau
Country [62] 0 0
Germany
State/province [62] 0 0
Gießen
Country [63] 0 0
Germany
State/province [63] 0 0
Greifswald
Country [64] 0 0
Germany
State/province [64] 0 0
Grosshansdorf
Country [65] 0 0
Germany
State/province [65] 0 0
Heidelberg
Country [66] 0 0
Germany
State/province [66] 0 0
Immenhausen
Country [67] 0 0
Germany
State/province [67] 0 0
Mainz
Country [68] 0 0
Germany
State/province [68] 0 0
München
Country [69] 0 0
Germany
State/province [69] 0 0
Münster
Country [70] 0 0
Greece
State/province [70] 0 0
Athens
Country [71] 0 0
Greece
State/province [71] 0 0
Heraklion
Country [72] 0 0
Greece
State/province [72] 0 0
Larisa
Country [73] 0 0
India
State/province [73] 0 0
Ahmedabad
Country [74] 0 0
India
State/province [74] 0 0
Bangalore
Country [75] 0 0
India
State/province [75] 0 0
Jaipur
Country [76] 0 0
India
State/province [76] 0 0
Kolkatta
Country [77] 0 0
India
State/province [77] 0 0
Mumbai
Country [78] 0 0
India
State/province [78] 0 0
Pune
Country [79] 0 0
Ireland
State/province [79] 0 0
Dublin
Country [80] 0 0
Israel
State/province [80] 0 0
Petah Tiqwa
Country [81] 0 0
Israel
State/province [81] 0 0
Rehovot
Country [82] 0 0
Italy
State/province [82] 0 0
Chieti Scalo
Country [83] 0 0
Italy
State/province [83] 0 0
Forli'
Country [84] 0 0
Italy
State/province [84] 0 0
Milano
Country [85] 0 0
Italy
State/province [85] 0 0
Modena
Country [86] 0 0
Italy
State/province [86] 0 0
Monza
Country [87] 0 0
Italy
State/province [87] 0 0
Napoli
Country [88] 0 0
Italy
State/province [88] 0 0
Padova
Country [89] 0 0
Italy
State/province [89] 0 0
Pisa
Country [90] 0 0
Italy
State/province [90] 0 0
Roma
Country [91] 0 0
Italy
State/province [91] 0 0
Siena
Country [92] 0 0
Japan
State/province [92] 0 0
Aichi, Nagoya
Country [93] 0 0
Japan
State/province [93] 0 0
Aichi, Seto
Country [94] 0 0
Japan
State/province [94] 0 0
Gifu, Ogaki
Country [95] 0 0
Japan
State/province [95] 0 0
Himeji, Hyogo
Country [96] 0 0
Japan
State/province [96] 0 0
Hyogo, Kobe
Country [97] 0 0
Japan
State/province [97] 0 0
Ibaraki, Naka-gun
Country [98] 0 0
Japan
State/province [98] 0 0
Kanagawa, Kawasaki
Country [99] 0 0
Japan
State/province [99] 0 0
Kanagawa, Yokohama
Country [100] 0 0
Japan
State/province [100] 0 0
Miyagi, Sendai
Country [101] 0 0
Japan
State/province [101] 0 0
Nara, Tenri
Country [102] 0 0
Japan
State/province [102] 0 0
Osaka, Osaka-sayama
Country [103] 0 0
Japan
State/province [103] 0 0
Saitama, Kumagaya
Country [104] 0 0
Japan
State/province [104] 0 0
Sakai, Osaka
Country [105] 0 0
Japan
State/province [105] 0 0
Tochigi, Shimotsuke
Country [106] 0 0
Japan
State/province [106] 0 0
Tokushima, Tokushima
Country [107] 0 0
Japan
State/province [107] 0 0
Tokyo, Bunkyo-ku
Country [108] 0 0
Japan
State/province [108] 0 0
Tokyo, Kiyose
Country [109] 0 0
Japan
State/province [109] 0 0
Tokyo, Minato-ku
Country [110] 0 0
Japan
State/province [110] 0 0
Tokyo, Ota-ku
Country [111] 0 0
Japan
State/province [111] 0 0
Tokyo, Shibuya-ku
Country [112] 0 0
Japan
State/province [112] 0 0
Tokyo, Shinjuku-ku
Country [113] 0 0
Japan
State/province [113] 0 0
Tottori, Yonago
Country [114] 0 0
Korea, Republic of
State/province [114] 0 0
Bucheon
Country [115] 0 0
Korea, Republic of
State/province [115] 0 0
Incheon
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Seoul
Country [117] 0 0
Mexico
State/province [117] 0 0
Mexico DF
Country [118] 0 0
Netherlands
State/province [118] 0 0
Amsterdam
Country [119] 0 0
Netherlands
State/province [119] 0 0
Nieuwegein
Country [120] 0 0
Netherlands
State/province [120] 0 0
Rotterdam
Country [121] 0 0
Portugal
State/province [121] 0 0
Coimbra
Country [122] 0 0
Portugal
State/province [122] 0 0
Lisboa
Country [123] 0 0
Portugal
State/province [123] 0 0
Porto
Country [124] 0 0
Portugal
State/province [124] 0 0
Vila Nova de Gaia
Country [125] 0 0
Russian Federation
State/province [125] 0 0
St. Petersburg
Country [126] 0 0
Spain
State/province [126] 0 0
Barcelona
Country [127] 0 0
Spain
State/province [127] 0 0
L´Hospitalet de Llobregat
Country [128] 0 0
Spain
State/province [128] 0 0
Sevilla
Country [129] 0 0
Turkey
State/province [129] 0 0
Ankara
Country [130] 0 0
Turkey
State/province [130] 0 0
Istanbul
Country [131] 0 0
Turkey
State/province [131] 0 0
Izmir
Country [132] 0 0
United Kingdom
State/province [132] 0 0
Aberdeen
Country [133] 0 0
United Kingdom
State/province [133] 0 0
Birmingham
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Leeds
Country [135] 0 0
United Kingdom
State/province [135] 0 0
Liverpool
Country [136] 0 0
United Kingdom
State/province [136] 0 0
London
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Oxford
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Westbury On Trym

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in
patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the
follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and
1199.34), who wish to continue treatment with BIBF 1120.
Trial website
https://clinicaltrials.gov/show/NCT01619085
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications